Atlas Trials

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Clinical trial NCT04466176 · COMPLETED

Trial details

NCT number
NCT04466176
Sponsor
Respirent Pharmaceuticals Co Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Bioequivalence
Start date
2020-07-01
Primary completion
2020-08-04
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.